1 Min Read
May 10 (Reuters) - Adaptimmune Therapeutics Plc
* Adaptimmune announces initiation of study to evaluate SPEAR T-cell therapy targeting AFP in liver cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.